Court: Actavis' Namenda hard switch 'coercion,' 'anticompetitive'
This article was originally published in Scrip
Executive Summary
A three-judge panel from the US Court of Appeals for the Second Circuit in New York on 22 May upheld a lower court's ruling ordering Actavis to keep its twice-daily immediate-release version of its Alzheimer's drug Namenda (memantine hydrochloride) on the US market – declaring the firm's plan for a "forced switch" to a newer version before generics are available is "coercion" and "anticompetitive."